What kind of drugs does Elafibranor belong to and what diseases does it mainly treat?

Elafibranor is a new oral small molecule drug that is a peroxisome proliferator-activated receptor (PPAR) agonist. Specifically, irafibratenol is a dual agonist of PPARα and PPARδ, which exerts therapeutic effects by regulating lipid metabolism, inflammatory response, and insulin sensitivity. Its unique mechanism makes it show potential in the field of metabolic diseases, especially in the treatment of fatty liver and metabolic syndrome.

Ilafibratenol is mainly used to treat non-alcoholic steatohepatitis (NASH), a chronic liver disease closely related to obesity, diabetes and other metabolic abnormalities. Fat accumulation in the liver of NASH patients is accompanied by inflammation and cell damage. If not treated in time, they may develop into cirrhosis or even liver cancer. Ilafibratenol improves liver lipid metabolism and inhibits inflammatory response by activating PPAR receptors, thereby reducing liver damage and reducing the risk of disease progression.

In addition to NASH, irafibratenol has also shown potential therapeutic effects in other metabolic diseases, such as type 2 diabetes and hyperlipidemia. By improving insulin sensitivity and regulating lipid levels, irafibratenol helps control blood sugar and lower blood lipids, thereby reducing many symptoms of metabolic syndrome. In addition, its anti-inflammatory properties also provide a theoretical basis for the treatment of related chronic diseases.
Currently, irafibratenol is still in the clinical trial stage and has not yet been widely approved for clinical treatment. However, multiple studies have shown its effectiveness and safety in the treatment of NASH. With the accumulation of further clinical data, irafibratenol is expected to become an important drug for the treatment of fatty liver and related metabolic diseases, providing patients with new treatment options.
Reference: https://www.drugs.com/donanemab.html